linjc16/ctgov huggingface dataset:
Circulating Tumor DNA as Liquid Biopsy in Patients With Stage IV Solid Tumors, a Feasibility Study at MUSC HCC

Study Overview
=================
Brief Summary
-----------------
To demonstrate the ability to detect specific cancer mutations in ctDNA isolated from plasma of stage IV cancer patients at HCC. To compare, in each patient, ctDNA longitudinal samples through treatment, and when available, with those of primary tumor and metastasis.

Detailed Description
-----------------
The overall goal of this study is to study circulating tumor DNA (ctDNA) in the blood to determine how cancer cells in patients react to treatment. DNA is short for deoxyribonucleic acid. DNA contains information that determines in part the traits, such as eye color, height, or disease risk, that are passed on from parent to child. This reaction will be measured by studying patient blood that will be collected before and during treatment until there is disease progression.

Official Title
-----------------
Circulating Tumor DNA as Liquid Biopsy in Patients With Stage IV Solid Tumors, a Feasibility Study at MUSC HCC

Conditions
-----------------
Solid Tumor, Adult

Intervention / Treatment
-----------------
* Procedure: research blood draws


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed diagnosis of stage IV malignancy, including any advanced solid tumors (including lymphoma) Eastern Cooperative Oncology Group (ECOG) performance Status (PS) 0-3 Life expectancy ≥ 3 months Patients must be able to provide consent Patients can be enrolled in other interventional clinical trials Exclusion Criteria: - Age < 18-year-old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Stage IV solid tumors<br>adult patients with stage IV cancer that are starting a new line of treatment | Procedure: research blood draws<br>* Twenty-five mL of peripheral blood (PB) will be collected for research. Blood will be collected in EDTA tubes and used to isolate ctDNA. For each subject we will request that he/she contribute 25 mL of plasma no more frequently than every 6 weeks, and at same time of standard of care blood draws and routine clinic visit, and for no more than 3 times (including baseline and end of study).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detecting specific cancer mutations in ctDNA isolated from plasma of stage IV cancer patients at HCC. |  | 24 months | 
| Changes in patients' ctDNA longitudinal samples through treatment, and when available, of primary tumor and metastasis. |  | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stage IV solid tumor
Effect of Ventilation Mode on Lung Deposition of a Radiolabeled Aerosol During Mechanical Ventilation: Barometric Versus Volumetric

Study Overview
=================
Brief Summary
-----------------
Controlling the respiratory pattern of mechanically ventilated patients in volume control mode is recommended during nebulization. No studies looked into conditions of nebulization during assisted mechanical ventilation to define the optimal nebulization technique and its effect on pulmonary deposition. The aim of this study is to analyse the effect of ventilation mode (barometric versus volumetric) on deposition by planar scintigraphy during mechanical ventilation.

Conditions
-----------------
Post-operative Neurosurgery

Intervention / Treatment
-----------------
* Drug: technetium-99m - Diethylenetriaminepentaacetic acid
* Device: Vibrating-mesh nebulizer
* Other: Gamma scintigraphy
* Other: Preoperative spirometry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Invasive mechanical ventilation Healthy lungs Exclusion Criteria: Change of ventilation mode during nebulization

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Nebulization during pressure support ventilation<br>Patients ventilated in pressure support mode during nebulization | Drug: technetium-99m - Diethylenetriaminepentaacetic acid<br> <br> Device: Vibrating-mesh nebulizer<br> <br> Other: Gamma scintigraphy<br> <br> Other: Preoperative spirometry<br> <br> |
| Active Comparator: Nebulization during volume assist control mode<br>Patients ventilated in volume assist control mode during nebulization | Drug: technetium-99m - Diethylenetriaminepentaacetic acid<br> <br> Device: Vibrating-mesh nebulizer<br> <br> Other: Gamma scintigraphy<br> <br> Other: Preoperative spirometry<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pulmonary deposition |  | Immediately after nebulization by imaging assessment, an expected average of 30 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Penetration index |  | Immediately after nebulization by imaging assessment, an expected average of 30 minutes | 
| Mechanical ventilation settings |  | During nebulisation time, an expected average of 15 minutes | 
| Lung function |  | Preoperative assessment, the day before inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aerosol, Lung deposition, Mechanical ventilation
Does Valproate Increase Levels of Folate Receptor Autoantibodies in Women?

Study Overview
=================
Brief Summary
-----------------
Women who take folate (folic acid) before getting pregnant can lower the risk of giving birth to infant with certain birth defects. However, some medications may affect the action of folate. The purpose of this study is to compare the effect of two anti-epileptic drugs on how folate works in our body.

Official Title
-----------------
Does Valproate Increase Levels of Folate Receptor Autoantibodies in Women?

Conditions
-----------------
Epilepsy, Psychiatric or Mood Diseases or Conditions

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women ages 18-50 years inclusive who are taking valproate or lamotrigine for neurologic or psychiatric conditions Valproate of lamotrigine must be used as monotherapy at stable doses for 6 weeks prior to the study for the neurologic or psychiatric illness; medications taken for other reasons are not excluded. Exclusion Criteria: Women with prior exposure to valproate or lamotrigine if they are taking lamotrigine or valproate respectively.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lamotrigine<br>No intervention | Other: No intervention<br>* No intervention. This is a cross-sectional study.<br>|
| Valproate<br>No intervention | Other: No intervention<br>* No intervention. This is a cross-sectional study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Levels of Folate Receptor Autoantibodies | ELISA assays using immobilized folate receptor protein were performed to determine the titers of immunoglobulin G, immunoglobulin M, and combined immunoglobulin G and immunoglobulin M to folate receptor in serum samples collected from both groups of women. | On the same day after informed consent was obtained | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Folate Receptor Autoantibodies, Epilepsy, Psychiatric conditions
Lung Ultrasonography in COVID-19 Pneumonia

Study Overview
=================
Brief Summary
-----------------
Lung ultrasonography has been used for diagnosis and treatment in many departments including intensive care before the pandemic. The gold standard method for the diagnosis of pneumonia is still chest tomography. Ultrasonography, which has advantages over tomography, has also been tried to be used in covid 19 pneumonia.

Detailed Description
-----------------
In this study, it was aimed to investigate the efficiency of lung ultrasonography in diagnosis of covid 19 pneumonia.

Official Title
-----------------
Comparison of Lung Ultrasonography Findings With Chest Computerized Tomography Results in Corona virüs (COVID-19) Pneumonia

Conditions
-----------------
Lung Ultrasound, Pneumonia, Covid19

Intervention / Treatment
-----------------
* Device: lung ultrasonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 and 85 years old Hospitalized in intensive care unit PCR tested Thoracic CT applied Exclusion Criteria: Previous lung and thoracic wall surgery Anatomically with thoracic wall disorder Patients who did not consent to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: lung ultrasound<br>lung ultrasonography protocol will be applied. | Device: lung ultrasonography<br>* Application of 12 zone lung ultrasonography protocol using the konvex ultrasound probe (2-6 MHz)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relationship between Thoracic CT imaging results and LUS results | Lung ultrasonography will be performed within 6 hours of the Thoracic CT. | 6 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characteristics of lesions | İdentifying the characteristics of the abnormal findings detected in Thoracic CT and LUS | 6 hours |
Coronary Vasomotor Response After Riociguat Exposure

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to assess the effects of intracoronary Riociguat on coronary blood flow in subjects with coronary artery disease and to compare this effect with the intracoronary nitroglycerin, a coronary vasodilator widly used to treat patients with coronary artery disease.

Official Title
-----------------
A Study to Compare the Acute Coronary Vasodilating Effects of the sGC Stimulator Riociguat (BAY 63-2521) With the Nitric Oxide Donor Nitroglycerin in Patients With Coronary Artery Disease

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Drug: Riociguat (BAY63-2521)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female patients with coronary artery disease Exclusion Criteria: Patents with coronary artery disease with >/= 70% luminal stenosis by coronary angiography in one of the 3 major epicardial coronary arteries (left anterior descending artery [LAD], left circumflex coronary artery [LCX] or right coronary artery [RCA]) undergoing cardiac catheterization

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br> | Drug: Riociguat (BAY63-2521)<br>* 0.1 mg intracoronary infusion through coronary guide catheter. Single dose. Sequential application after initial vasoactive bolus of Adenosine (non-study drug) and Nitroglycerin (non-study drug).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The ratio of the coronary blood flow after Riociguat to the corresponding flow observed after adenosine, compared to that after nitroglycerin administration |  | Within 5 min after completion of the intracoronary Riociguat infusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse event collection |  | Until 30 days after study drug treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Coronary artery disease
Proof-of-Concept Study Assessing VNS Paired With Tones for Tinnitus

Study Overview
=================
Brief Summary
-----------------
This is a proof-of-concept study designed to provide feasibility information on the clinical use of vagus nerve stimulation (VNS) paired with tones for the treatment of severe tinnitus. The study is expected to give preliminary efficacy and safety information.

Official Title
-----------------
A Proof-of-Concept Pilot Study Assessing Vagus Nerve Stimulation (VNS) Paired With Tones for Tinnitus

Conditions
-----------------
Severe Tinnitus

Intervention / Treatment
-----------------
* Device: vagus nerve stimulation (VNS)


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: 18 to 65 years of age Diagnosed with subjective tinnitus due to hearing loss with at least some tonal quality of the tinnitus. Diagnosis of tinnitus for at least one year Tinnitus severity of 18 or greater on TRQ cross checked with TQ severity of Grade 3 or worse Key Exclusion Criteria: Acute or intermittent tinnitus Severe hearing loss History of significant ear disease such as Meniere's disease, ear tumors, or evidence of active middle ear disease. Any other implanted device

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: VNS plus tones<br> | Device: vagus nerve stimulation (VNS)<br>* Daily stimulation synchronized with tones at the study assigned dose (amplitude, frequency, on/off cycle and treatment period).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Audiometric measurements |  | weekly through one month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| tinnitus questionaires |  | weekly through one month | 
| adverse events |  | as they occur |
Prolongation of Pain Free Time by the Use of Dexamethasone in Peripheral Nerve Blockade

Study Overview
=================
Brief Summary
-----------------
The main aim of the study is to investigate the proven effect of dexamethsone on the duration of the interscalene block. The investigators try to define optimal dose and volume for ropivacaine, when used together with dexamethsone. The current literature uses often very high volumes of ropivacain when used together with dexamethasone. The investigators try to research the effect of using dexamethsone together with low volume, high concentration ropivacaine for interscalene blockade. The investigators' hypothesis is that dexamethasone has an positive effect on the pain free after used together with ropivacaine at the scalene block.

Official Title
-----------------
The Effect of Dexamethasone Used Together With Low Volume Ropivacaine in a Single Shot Interscalene Block on the Pain Free Time Experienced by the Patient

Conditions
-----------------
Interscalene Block, Shoulder Arthroscopy, Dexamethasone, Low Volume Regional Anesthesia

Intervention / Treatment
-----------------
* Drug: Dexamethasone acetate
* Drug: Placebo
* Drug: Ropivacaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: atroscopy of the shoulder repair of the RM Exclusion Criteria: patient under 18 years patient is fertile chronic opiat use more than 30mg oxycodone per day operations at the shoulder that involves the bone usage of cortisone for more than 2 weeks risk greater as asa III damage to nerves neuropathy at the target arm

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Verum<br>Dexamethasone and Ropivacaine | Drug: Dexamethasone acetate<br> <br> Drug: Ropivacaine<br> <br> |
| Active Comparator: Placebo<br>Ropivacaine and Saline | Drug: Placebo<br> <br> Drug: Ropivacaine<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain free time measured by the duration between block and the point at which the patient is asking for painkillers |  | Patients will be followed during their stay at the hospital, which will be normally around 24 to 48 hours. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Rating Scale for Pain at Movement and Rest |  | Measured 10 hours after the intervention |
Postoperative Lactate and Atrial Fibrillation After CABG

Study Overview
=================
Brief Summary
-----------------
Postoperative atrial fibrillation (POAF) is associated with increased mortality and morbidity in patients undergoing isolated coronary artery bypass grafting (CABG). It has been estimated that 5-40% of CABG patients experience POAF. Advanced age, P wave abnormalities, left atrial dilation, emergency surgery, low left ventricle ejection fraction, low glomerular filtration rate and chronic obstructive pulmonary disease have been reported in the etiology. Predicting which patients would experience POAF following CABG is important since it would allow physicians to apply more focused prophylactic measures. Lactate is the final product of anaerobic glycolysis. Serum lactate level are increased in case of inadequate oxygen delivery to tissues. The investigators aim to assess whether serum lactate levels measured early in the postoperative period could be used as a predictive marker of POAF in adults undergoing isolated CABG.

Official Title
-----------------
Association of Postoperative Lactate Levels With Postoperative Atrial Fibrillation in Patients Undergoing Isolated Coronary Artery Bypass Graft Surgery

Conditions
-----------------
Coronary Artery Disease, Atrial Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Undergoing isolated CABG Age >18 years Exclusion Criteria: Age <18 years Pregnancy History of paroxysmal atrial fibrillation prior to surgery Undergoing concomitant procedures (e.g., CABG + valve surgery) Any preoperative cardiac rhythm other than normal sinus rhythm More than mild cardiac valve stenosis or insufficiency

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Low lactate<br>Patients with a low lactate level defined by logistic regression analysis. | |
| High lactate<br>Patients with a high lactate level defined by logistic regression analysis. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative atrial fibrillation | New-onset atrial fibrillation occurring in the immediate period after CABG | 30 days |
Pre-surgical CT Scan Assessment of Bone Mineral Density Before Resection of NHO of the Hip

Study Overview
=================
Brief Summary
-----------------
Neurogenic heterotopic ossification (NHO) is defined as an ectopic ossification around proximal joints usually seen after traumatic brain injury, spinal cord injury or polytrauma. NHO causes pain, partial or total joint ankylosis and vascular or nerve complications. The osteopenia (low bone density) induced by ankylose increases the fracture risk of femoral neck during the hip surgery performed to remove the NHO. The analyse of femoral head bone mineral density from hip pre-surgical CT scan could anticipate this kind of complication establishing a presurgical prognostic. If as it turns out the bone density measured from hip pre-surgical CT scan is relevant fracture risk marker, a preventive osteosynthesis or femoral head and neck resection could be performed in the same time of NHO resection.

Official Title
-----------------
Pre-surgical CT Scan Assessment of Femoral Head Bone Mineral Density Before Resection of Neurogenic Heterotopic Ossification (NHO) of the Hip

Conditions
-----------------
Paraosteoarthropathies

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged 18 years and over Patients having surgery resection of surgery resection of Neurogenic heterotopic ossification of hip. Patients with pre-surgery CT-scan and surgery report available Exclusion criteria: Minor patients Patients didn't have surgery surgery resection of Neurogenic heterotopic ossification of hip. Pre-surgery CT-scan and surgery report not available Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| femoral head bone mineral density | femoral head bone mineral density | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hip surgery, bone mineral density, femoral head, Pre-surgical prognostic